⭐️⭐️⭐️⭐️⭐️ "A total no brainer"

⭐️⭐️⭐️⭐️⭐️ "Love this, so easy."

Spots is the easy way to track your skin, mole and cancer changes.

Spots Global Cancer Trial Database for loss of chromosome 17p

Every month we try and update this database with for loss of chromosome 17p cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Study titleNCT IDConditionsInterventionsEligibilityOrganizationLink
Irradiated Donor Cells Following Stem Cell Transplant in Controlling Cancer in Patients With Hematologic MalignanciesNCT03272633
Acute Lymphobla...
Acute Myeloid L...
Hematopoietic C...
JAK2 Gene Mutat...
Loss of Chromos...
Mantle Cell Lym...
Minimal Residua...
Myelodysplastic...
Non-Hodgkin Lym...
Plasma Cell Mye...
RAS Family Gene...
Recurrent Diffu...
Recurrent Hemat...
Recurrent Matur...
Refractory Diff...
Refractory Matu...
Therapy-Related...
Therapy-Related...
TP53 Gene Mutat...
Allogeneic Hema...
Irradiated Allo...
18 Years - Rutgers, The State University of New Jersey
Autologous Peripheral Blood Stem Cell Transplant Followed by Donor Bone Marrow Transplant in Treating Patients With High-Risk Hodgkin Lymphoma, Non-Hodgkin Lymphoma, Multiple Myeloma, or Chronic Lymphocytic LeukemiaNCT01008462
B-Cell Prolymph...
Hypodiploidy
Loss of Chromos...
Plasma Cell Leu...
Progression of ...
Recurrent Adult...
Recurrent Adult...
Recurrent Child...
Recurrent Child...
Recurrent Chron...
Recurrent Plasm...
Recurrent Small...
Refractory Chil...
Refractory Chro...
Refractory Non-...
Refractory Plas...
Refractory Smal...
t(14;16)
t(4;14)
T-Cell Prolymph...
Waldenstrom Mac...
Allogeneic Bone...
Allogeneic Hema...
Autologous Hema...
Autologous-Allo...
Carmustine
Cyclophosphamid...
Cytarabine
Etoposide
Fludarabine Pho...
Laboratory Biom...
Melphalan
Mycophenolate M...
Peripheral Bloo...
Tacrolimus
Total-Body Irra...
- 75 YearsFred Hutchinson Cancer Center
Bortezomib, Total Marrow Irradiation, Fludarabine Phosphate, and Melphalan in Treating Patients Undergoing Donor Peripheral Blood Stem Cell Transplant For High-Risk Stage I or II Multiple MyelomaNCT01163357
Autologous Hema...
Loss of Chromos...
Plasma Cell Leu...
Recurrent Plasm...
Refractory Plas...
bortezomib
fludarabine pho...
melphalan
total marrow ir...
tacrolimus
sirolimus
peripheral bloo...
laboratory biom...
18 Years - 70 YearsCity of Hope Medical Center
Idasanutlin, Ixazomib Citrate, and Dexamethasone in Treating Patients With Relapsed Multiple MyelomaNCT02633059
Loss of Chromos...
Recurrent Plasm...
Dexamethasone
Idasanutlin
Ixazomib Citrat...
Laboratory Biom...
Pharmacological...
18 Years - Mayo Clinic
Irradiated Donor Cells Following Stem Cell Transplant in Controlling Cancer in Patients With Hematologic MalignanciesNCT03272633
Acute Lymphobla...
Acute Myeloid L...
Hematopoietic C...
JAK2 Gene Mutat...
Loss of Chromos...
Mantle Cell Lym...
Minimal Residua...
Myelodysplastic...
Non-Hodgkin Lym...
Plasma Cell Mye...
RAS Family Gene...
Recurrent Diffu...
Recurrent Hemat...
Recurrent Matur...
Refractory Diff...
Refractory Matu...
Therapy-Related...
Therapy-Related...
TP53 Gene Mutat...
Allogeneic Hema...
Irradiated Allo...
18 Years - Rutgers, The State University of New Jersey
Ibrutinib and Venetoclax in Treating Patients With Chronic Lymphocytic Leukemia After Ibrutinib ResistanceNCT03943342
Chronic Lymphoc...
Loss of Chromos...
Ibrutinib
Venetoclax
18 Years - Ohio State University Comprehensive Cancer Center
a Clinical Trial of Efficacy and Safety of the Holistic Treatment of Young High-risk Multiple Myeloma PatientsNCT04008888
Multiple Myelom...
Plasma Cell Leu...
Extramedullary ...
Loss of Chromos...
t(14;16)
t(4;14)
T(14;20)
1Q21 Amplificat...
Complex Karyoty...
Allogeneic Hema...
Autologous Hema...
Melphalan Given...
Fludarabine Inj...
PI and dexameth...
PI+IMids+Dexame...
18 Years - 60 YearsInstitute of Hematology & Blood Diseases Hospital, China
Nivolumab and Ibrutinib in Treating Patients With Relapsed, Refractory, or High-Risk Untreated Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or Richter TransformationNCT02420912
Loss of Chromos...
Recurrent Chron...
Recurrent Small...
Refractory Chro...
Refractory Smal...
Richter Syndrom...
Ibrutinib
Laboratory Biom...
Nivolumab
18 Years - M.D. Anderson Cancer Center
Idasanutlin, Ixazomib Citrate, and Dexamethasone in Treating Patients With Relapsed Multiple MyelomaNCT02633059
Loss of Chromos...
Recurrent Plasm...
Dexamethasone
Idasanutlin
Ixazomib Citrat...
Laboratory Biom...
Pharmacological...
18 Years - Mayo Clinic
Bortezomib, Total Marrow Irradiation, Fludarabine Phosphate, and Melphalan in Treating Patients Undergoing Donor Peripheral Blood Stem Cell Transplant For High-Risk Stage I or II Multiple MyelomaNCT01163357
Autologous Hema...
Loss of Chromos...
Plasma Cell Leu...
Recurrent Plasm...
Refractory Plas...
bortezomib
fludarabine pho...
melphalan
total marrow ir...
tacrolimus
sirolimus
peripheral bloo...
laboratory biom...
18 Years - 70 YearsCity of Hope Medical Center
Logo

Take Control of Your Skin and Body Changes Today.

Try out Spots for free, set up only takes 2 mins.

spots app storespots app store

Join others from around the world: